Action Frazier LifeSciences Acq... - FLAC

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

Dernier

9,87

Prix Achat

10,00

Prix Vente

12,75

Volume échangé

0,00 Fourchette du Jour 0,00

0,00 Plage de 52 semaines 0,00

Clôture Veille

9,87

Ouverture

Dernière Transaction

Dernière heure de transaction

Volume moyen (3 m)

Volume financier

VWAP

NewAmsterdam Pharma Debuts as Publicly Traded Company Focused on Developing Obicetrapib, a Low-Dose, Once-Daily Oral LDL-Lowering Agent with Promising Safety and Efficacy Clinical Data, as a Potential Preferred Therapy for High Risk Cardiovascular Disease

-- Business combination transaction with Frazier Lifesciences Acquisition Corporation, a special purpose acquisition company sponsored by an affiliate of Frazier Healthcare Partners, completed on...

Frazier Lifesciences Acquisition Corporation Shareholders Approve Business Combination with NewAmsterdam Pharma Holding B.V.

Frazier Lifesciences Acquisition Corporation (Nasdaq: FLAC) (“FLAC”), a special purpose acquisition company sponsored by an affiliate of Frazier Healthcare Partners, announced today that its...

Phathom Pharmaceuticals Appoints Dr. James Topper to its Board of Directors

FLORHAM PARK, N.J., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for...

NewAmsterdam Pharma Holding B.V. and Frazier Lifesciences Acquisition Corporation Announce Merger Agreement to Create Publicly Listed Company Focused on Transformative Oral Therapies for Major Cardiometabolic Diseases

– Leading institutional investors commit approximately $235 million through an oversubscribed and upsized private investment in public equity (“PIPE”) led by Frazier Healthcare Partners and Bain...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

FLAC - Frequently Asked Questions (FAQ)

What is the current Frazier LifeSciences Acq... share price?

The current share price of Frazier LifeSciences Acq... is US$ 9,87

What is the 1 year trading range for Frazier LifeSciences Acq... share price?

Frazier LifeSciences Acq... has traded in the range of US$ 0,00 to US$ 0,00 during the past year

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
MGOLMGO Global Inc	US$ 0,40 (116,22%)	150,48M
CDTConduit Pharmaceuticals Inc	US$ 3,13 (101,94%)	3,43M
UPCUniverse Pharmaceuticals Inc	US$ 0,2634 (63,60%)	81,6M
RANDRand Capital Corporation	US$ 36,74 (59,67%)	12
ZOOZZOOZ Power Ltd	US$ 3,22 (56,31%)	46
BTMDBiote Corporation	US$ 2,07 (-56,96%)	43
ANIKAnika Therapeutics Inc	US$ 8,00 (-55,03%)	20
EDRYEuroDry Ltd	US$ 6,01 (-45,01%)	4
NKLANikola Corporation	US$ 0,4499 (-40,21%)	3,77M
PFCPremier Financial Corporation	US$ 17,01 (-39,89%)	5
MGOLMGO Global Inc	US$ 0,40 (116,22%)	150,48M
UPCUniverse Pharmaceuticals Inc	US$ 0,2634 (63,60%)	81,6M
NIVFNewGenIvf Group Ltd	US$ 0,19 (22,50%)	33,76M
LTRYLottery com Inc	US$ 1,7306 (22,74%)	27,02M
RIMEAlgorhythm Holdings Inc	US$ 0,0202 (-5,16%)	20,81M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Frazier LifeSciences Acquisition Corporation (FLAC)

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

FLAC Dernières nouvelles

NewAmsterdam Pharma Debuts as Publicly Traded Company Focused on Developing Obicetrapib, a Low-Dose, Once-Daily Oral LDL-Lowering Agent with Promising Safety and Efficacy Clinical Data, as a Potential Preferred Therapy for High Risk Cardiovascular Disease

Frazier Lifesciences Acquisition Corporation Shareholders Approve Business Combination with NewAmsterdam Pharma Holding B.V.

Phathom Pharmaceuticals Appoints Dr. James Topper to its Board of Directors

NewAmsterdam Pharma Holding B.V. and Frazier Lifesciences Acquisition Corporation Announce Merger Agreement to Create Publicly Listed Company Focused on Transformative Oral Therapies for Major Cardiometabolic Diseases

FLAC - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Frazier LifeSciences Acquisition Corporation (FLAC) Cours

Frazier LifeSciences Acquisition Corporation (FLAC)

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

FLAC Dernières nouvelles

NewAmsterdam Pharma Debuts as Publicly Traded Company Focused on Developing Obicetrapib, a Low-Dose, Once-Daily Oral LDL-Lowering Agent with Promising Safety and Efficacy Clinical Data, as a Potential Preferred Therapy for High Risk Cardiovascular Disease

Frazier Lifesciences Acquisition Corporation Shareholders Approve Business Combination with NewAmsterdam Pharma Holding B.V.

Phathom Pharmaceuticals Appoints Dr. James Topper to its Board of Directors

NewAmsterdam Pharma Holding B.V. and Frazier Lifesciences Acquisition Corporation Announce Merger Agreement to Create Publicly Listed Company Focused on Transformative Oral Therapies for Major Cardiometabolic Diseases

FLAC - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS